Na Zhou

690 total citations
33 papers, 488 citations indexed

About

Na Zhou is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Na Zhou has authored 33 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Na Zhou's work include MicroRNA in disease regulation (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immune cells in cancer (5 papers). Na Zhou is often cited by papers focused on MicroRNA in disease regulation (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immune cells in cancer (5 papers). Na Zhou collaborates with scholars based in China, Macao and United States. Na Zhou's co-authors include Chunmei Bai, Zhao Sun, Qin Han, Shan Lu, Shihua Wang, Robert Chunhua Zhao, Changting Meng, Yingyi Wang, Mei Guan and Xiaoyuan Li and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and Biomaterials.

In The Last Decade

Na Zhou

29 papers receiving 482 citations

Peers

Na Zhou

ONCOL

IMMUN

PRM

Jian Xie China

Patrick A. Candy Australia

Shao‐Lan Qin China

Renba Liang China

Zhuqing Zhou China

Meng Xie China

Jing Xun China

Fuao Cao China

Deli Mao China

Bo Ni China

Jian Xie China

Na Zhou

365 ×1.4

234 ×1.0

154 ×1.0

ONCOL

67 ×0.7

IMMUN

56 ×1.0

PRM

Citations per year, relative to Na Zhou Na Zhou (= 1×) peers Jian Xie

Countries citing papers authored by Na Zhou

Since Specialization

Citations

This map shows the geographic impact of Na Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Zhou more than expected).

Fields of papers citing papers by Na Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Na Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Zhou. The network helps show where Na Zhou may publish in the future.

Co-authorship network of co-authors of Na Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Na Zhou. A scholar is included among the top collaborators of Na Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Na Zhou. Na Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Xiaohua, Yueyang Zhang, Bailing Zhou, et al.. (2025). Intestinal Probiotic Lysate Modified Bifunctional Nanoparticle for Efficient Colon Cancer Immunotherapy. Pharmaceutics. 17(2). 139–139. 1 indexed citations

Chen, Xiaohua, Shuai Ming, Yan Gao, et al.. (2025). Efficient cancer immunogenetherapy by tumor cell lysate modified mRNA formulation. Biomaterials. 324. 123466–123466. 1 indexed citations

Ma, Yueyue, et al.. (2025). Surface-enhanced Raman spectroscopy facilitates the detection of multiple metabolic modulators. Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy. 337. 126121–126121.

Wu, Jie, Xiaojun Tang, Na Zhou, et al.. (2024). Study of Urinary Protein Biomarkers in Hereditary Angioedema. Journal of Investigational Allergology and Clinical Immunology. 35(5). 353–363.

Zhou, Na, et al.. (2024). Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study. Frontiers in Immunology. 15. 1482005–1482005. 3 indexed citations

Zhou, Na, et al.. (2024). Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53. Lung Cancer. 199. 108068–108068.

Sun, Mingna, Weijie Peng, Zhongxiao Lin, et al.. (2024). Hyaluronic acid modified nanocarriers for aerosolized delivery of verteporfin in the treatment of acute lung injury. International Journal of Biological Macromolecules. 267(Pt 1). 131386–131386. 5 indexed citations

Zhou, Na, et al.. (2023). Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion. Lung Cancer. 183. 107289–107289.

Tang, Hui, Zhu Zhou, Tingting You, et al.. (2023). The prognostic role of WeChat-based instant doctor–patient communication in patients with advanced pancreatic cancer. Journal of Cancer Survivorship. 18(6). 1903–1911. 2 indexed citations

10.

Tang, Hui, Tingting You, Sijian Li, et al.. (2023). Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients. Frontiers in Immunology. 14. 1125876–1125876. 16 indexed citations

11.

Zhou, Na, Hui Tang, Simon C.H. Yu, et al.. (2022). Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma. Frontiers in Immunology. 13. 1001414–1001414. 5 indexed citations

12.

Liu, Hongsheng, Yingzhi Qin, Na Zhou, Dongjie Ma, & Yingyi Wang. (2021). ZNF280A promotes lung adenocarcinoma development by regulating the expression of EIF3C. Cell Death and Disease. 12(1). 39–39. 15 indexed citations

13.

Wang, Yingyi, Na Zhou, Rui Zhu, et al.. (2021). Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression. BMC Pulmonary Medicine. 21(1). 282–282. 15 indexed citations

14.

Yu, Shuangni, Huilin Shao, Hongkai Zhang, et al.. (2019). Detection of POLE Subtypes in High-Grade Endometrioid Carcinoma by BaseScope-ISH Assay. Frontiers in Oncology. 9. 831–831. 19 indexed citations

15.

Zhou, Na, Yi Lin, Xianghong Peng, Yingyi Wang, & Yuzhou Wang. (2019). Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease. Lung Cancer. 138. 116–123. 15 indexed citations

16.

Zhou, Na, et al.. (2016). [Effect and mechanism of traditional Chinese herbs against Aβ expression in brain tissues of mice with Alzheimer's disease].. PubMed. 45(11). 780–785. 8 indexed citations

17.

Zhou, Na, Jinhua Wu, Xiang Wang, et al.. (2015). Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma. Tumor Biology. 37(2). 2145–2152. 13 indexed citations

18.

Sun, Zhi‐Gang, Na Zhou, Qin Han, et al.. (2015). MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer. Clinical & Translational Oncology. 17(11). 876–883. 33 indexed citations

19.

Sun, Zhao, Changting Meng, Shihua Wang, et al.. (2014). MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. BMC Cancer. 14(1). 616–616. 82 indexed citations

20.

Sun, Zhao, Qin Han, Na Zhou, et al.. (2013). MicroRNA‐9 enhances migration and invasion through KLF17 in hepatocellular carcinoma. Molecular Oncology. 7(5). 884–894. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact